TRAW (Traws Pharma) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Traws Pharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Traws Pharma's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Traws Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Traws Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma LT-Debt-to-Total-Asset Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Traws Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Traws Pharma LT-Debt-to-Total-Asset Calculation

Traws Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	22.683
	=	0.00

Traws Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	8.936
	=	0.00

Traws Pharma (NAS:TRAW) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Traws Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Traws Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Executives

Victor M Moyo	officer: CHIEF MEDICAL OFFICER	12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke	director	12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja	director	12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler	officer: VP Corp Dev & Gen Counsel	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman	officer: Chief Medical Officer	375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md	officer: Chief Medical Officer	C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin	officer: Chief Accounting Officer	375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker	director	375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy	director	375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman	director	C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta	director	OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P	10 percent owner	150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022